We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene Panel Differentiates Survival Outcomes in Humans Infected with Ebola

By LabMedica International staff writers
Posted on 31 Jan 2017
A team of molecular virologists used transcriptome data from individuals infected with Ebola virus and from convalescent patients recovering from the disease to identify early stage host factors that were associated with the acute illness and those that differentiated patients who survived from those that died.

The transcriptome is the set of all messenger RNA molecules in one cell or a population of cells. More...
It differs from the exome in that it includes only those RNA molecules found in a specified cell population, and usually includes the amount or concentration of each RNA molecule in addition to the molecular identities.

Investigators at the University of Liverpool used genomic techniques to identify and quantify messenger RNA (mRNA) expression in the blood of Ebola patients in Guinea who either went on to survive or die from the acute infection. These results were compared to blood samples from a separate group of survivors who had recovered from infection and were now free of the Ebola virus.

Results revealed that individuals who succumbed to the disease showed stronger upregulation of interferon signaling and acute phase responses compared to survivors during the acute phase of infection. Particularly notable was the strong upregulation of albumin and fibrinogen genes, which suggested significant liver pathology. Cell subtype prediction using messenger RNA expression patterns indicated that NK-cell populations increased in patients who survived infection.

Differences in immune cell populations predicted through analysis of gene expression patterns were validated on an independent group of Ebola virus patients using flow cytometry to directly measure the same cell types in patient blood. Machine learning was used to identify a panel of genes whose abundance could be used to predict the outcome of infection at the acute phase. This panel was validated on a separate independent group of patients with fatal or non-fatal outcome and whose viral loads were similar and was found to accurately predict outcome.

Senior author Dr. Julian Hiscox, professor of virology at the University of Liverpool, said, "Our study provides a benchmark of Ebola virus infection in humans and suggests that rapid analysis of a patient's response to infection in an outbreak could provide valuable predictive information on disease outcome."

The study was published in the January 19, 2017, online edition of the journal Genome Biology.


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.